Precision BioSciences says safety board clears further dosing in Phase 1/2 PBGENE-DMD Duchenne trial

Precision BioSciences says its safety board cleared further dosing in the Phase 1/2 PBGENE-DMD Duchenne muscular dystrophy trial after no serious adverse events were seen in the first patient.

Detected & updated continuously · Source: Nebula